Gastroesophageal Junction Adenocarcinoma Clinical Trials in Shanghai, Shanghai Municipality
12 recruitingShanghai, Shanghai Municipality, China
Showing 1–12 of 12 trials
Recruiting
Phase 1Phase 2
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited132 enrolled30 locationsNCT07327229
Recruiting
Phase 2
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Fudan University276 enrolled1 locationNCT07492615
Recruiting
Phase 1
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Hansoh BioMedical R&D Company40 enrolled1 locationNCT07462923
Recruiting
Phase 2
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.258 enrolled1 locationNCT05671822
Recruiting
Phase 3
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.600 enrolled2 locationsNCT07118527
Recruiting
Phase 3
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.560 enrolled68 locationsNCT07284134
Recruiting
Phase 3
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
Gastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.490 enrolled2 locationsNCT07152405
Recruiting
Phase 2
A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.40 enrolled1 locationNCT06423885
Recruiting
Phase 2
The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital50 enrolled1 locationNCT06587425
Recruiting
Phase 2Phase 3
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.90 enrolled12 locationsNCT06221748
Recruiting
Phase 1
Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
Pancreatic CancerGastric CancerGastroesophageal Junction Adenocarcinoma+1 more
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled1 locationNCT05472857
Recruiting
Phase 3
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd.360 enrolled1 locationNCT06123494